These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 33295801

  • 1. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA, Radzinsky E, Tirumani SH, Guler E, Petraszko A, Kikano E, Hoimes CJ, Ramaiya NH.
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [Abstract] [Full Text] [Related]

  • 2. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
    Nobashi TW, Nishimoto Y, Kawata Y, Yutani H, Nakamura M, Tsuji Y, Yoshida A, Sugimoto A, Yamamoto T, Alam IS, Noma S.
    Br J Radiol; 2020 Nov 01; 93(1115):20200409. PubMed ID: 32783627
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
    Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S.
    Cancer Med; 2021 Jul 01; 10(14):4796-4804. PubMed ID: 34121358
    [Abstract] [Full Text] [Related]

  • 5. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
    Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K.
    J Natl Compr Canc Netw; 2023 Nov 01; 21(11):1164-1171.e5. PubMed ID: 37935100
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X, Wang J, Zhang T, Zhou Z, Deng L, Wang X, Wang W, Liu W, Tang W, Wang Z, Wang J, Jiang W, Bi N, Wang L.
    Front Immunol; 2022 Nov 01; 13():918787. PubMed ID: 35795657
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G, Khaddar S, Gupta K, Rathinasamy N, Srinivas S, Agrawal A, Ventrapati P, Prabhash K.
    Cancer Med; 2021 Mar 01; 10(5):1525-1534. PubMed ID: 33591635
    [Abstract] [Full Text] [Related]

  • 11. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, Yanagisawa T, Takayanagi N.
    Thorac Cancer; 2021 Jan 01; 12(2):153-164. PubMed ID: 33201587
    [Abstract] [Full Text] [Related]

  • 12. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K.
    Sci Rep; 2020 Aug 13; 10(1):13773. PubMed ID: 32792640
    [Abstract] [Full Text] [Related]

  • 13. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.
    Hu Q, Wang S, Ma L, Sun Z, Liu Z, Deng S, Zhou J.
    J Cell Mol Med; 2024 Mar 13; 28(5):e17895. PubMed ID: 37525480
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
    Sun Z, Wang S, Du H, Shen H, Zhu J, Li Y.
    Invest New Drugs; 2021 Jun 13; 39(3):891-898. PubMed ID: 33428078
    [Abstract] [Full Text] [Related]

  • 15. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
    Canale ML, Camerini A, Casolo G, Lilli A, Bisceglia I, Parrini I, Lestuzzi C, Del Meglio J, Puccetti C, Camerini L, Amoroso D, Maurea N.
    Adv Ther; 2020 Jul 13; 37(7):3178-3184. PubMed ID: 32436027
    [Abstract] [Full Text] [Related]

  • 16. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
    Cheng J, Pan Y, Huang W, Huang K, Cui Y, Hong W, Wang L, Ni D, Tan P.
    Med Phys; 2022 Mar 13; 49(3):1547-1558. PubMed ID: 35026041
    [Abstract] [Full Text] [Related]

  • 17. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.
    Respir Investig; 2019 Sep 13; 57(5):451-459. PubMed ID: 31248832
    [Abstract] [Full Text] [Related]

  • 18. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, Curran WJ, Higgins KA.
    Int J Radiat Oncol Biol Phys; 2020 Sep 01; 108(1):304-313. PubMed ID: 31982496
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab.
    Kudu E, Akdag G, Yildirim ME.
    Support Care Cancer; 2024 Sep 09; 32(10):646. PubMed ID: 39251491
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y.
    Clin Lung Cancer; 2019 Nov 09; 20(6):442-450.e4. PubMed ID: 31446020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.